When Arrowhead Pharmaceuticals embarked on a $220 million expansion in Wisconsin, WEDC partnered with the firm to help it become a reality.

The project, which has broken ground in Verona, will create more than 230 jobs at the genetic medicine company, which recognizes the benefits of the state’s strong biotechnology climate.

“We have seen firsthand the tremendous value that the Wisconsin biotech ecosystem can afford a nimble and aggressive company like Arrowhead,” said Christopher Anzalone, president and CEO of Arrowhead Pharmaceuticals. “We look forward to this expansion contributing to the further growth in the region as we work to make medicines with a potential global impact.”

Click here to read the full article.